MBX Biosciences Reports One-Year Canvuparatide Data with 57% Responder Rate

MBX announced sustained one-year efficacy data for once-weekly canvuparatide in chronic hypoparathyroidism, with a 57% responder rate and high 90% retention. The company remains on track to initiate Phase 3 pivotal trials in Q3 2026, supporting advancement toward commercialization of this potential PTH replacement therapy.